Full Press Release Details
Aurora Announces Investment into German Manufacturing
Facility investment includes
adopting the company's unmatched global manufacturing practices for superior cannabis production and quality
EDMONTON, AB, Sept. 18, 2025 /CNW/ - Aurora Cannabis
Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces an investment over five years into
operational upgrades at its EU-GMP manufacturing facility in Leuna, Germany. Building on best practices proven at Aurora's Canadian facilities,
these improvements will increase flower growth capacity, product quality and drive cost efficiency.
"This investment marks a significant milestone
in our commitment to operational excellence and long-term growth in Europe," said Alex Miller, Executive Vice President of Operations,
Science and Supply Chain at Aurora. "These upgrades will strengthen our supply chain resilience, expand our domestic capabilities
in EU-GMP certified manufacturing, and position us to best meet the growing demand for high-quality medical cannabis in Europe with precision
Aurora's global manufacturing network upholds the
highest manufacturing standards that will be adopted at the German facility. With the goal of maximizing cultivation volume, the upgrades
include commissioning additional grow rooms, new irrigation and lighting systems in existing rooms, and transitioning to hang dry and
As one of only three licensed cultivation facilities
in the country, Aurora Leuna plays a pivotal role in supplying high-quality, locally grown medical cannabis to meet the needs of Germany's
expanding patient base. Aurora Leuna currently grows cultivars under the IndiMed brand, and this expansion will enable the site to grow
additional cultivars available from Aurora's leading genetics library. By continuously investing in operational capabilities, Aurora is
best positioned to serve international markets at the highest standards.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both
the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer
in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael
'71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana
Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North
America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis
products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever
Aurora's common shares trade on the NASDAQ and TSX
under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project",
"intend", "believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur.
Forward-looking statements in this news release include, but are not limited to, those regarding: (i) the Company's planned investment
into operational upgrades at its manufacturing facility in Leuna, Germany; (ii) the expected benefits including increased flower growth
capacity, product quality and cost efficiencies, the strengthening of the Company's supply chain resilience, expansion to the Company's
domestic capabilities in EU-GMP certified manufacturing, and the positioning of the Company to best meet the growing demand in Europe;
and (iii) the Company's commitment and ability to continue to serve international markets at the highest standards.
These forward-looking statements are only predictions.
Forward looking information or statements contained in this news release have been developed based on assumptions management considers
to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from market research and industry analysis and on assumptions based on data
and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks,
uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events,
results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking
statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods
imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure
to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and
retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand
in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration
of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability
to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield
from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes
in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and
factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF")
and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed
with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described
in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties
and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-announces-investment-into-german-manufacturing-facility-302559847.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2025/18/c0668.html
For further information: For Media: Michelle Lefler | VP, Communications
& PR | media@auroramj.com; For Investors: ICR, Inc. | aurora@icrinc.com
CO: Aurora Cannabis Inc.
CNW 07:00e 18-SEP-25